Mary Ann Liebert: Understanding What Causes Trastuzumab's Cardiotoxicity
March 19, 2024
March 19, 2024
NEW ROCHELLE, New York, March 19 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new meta-analysis published in the peer-reviewed OMICS: A Journal of Integrative Biology helps shed light on how changes in mitochondria-related gene expression may cause the cardiotoxicity associated with the cancer therapy trastuzumab. Click here (https://email.liebertpub.com/c/11d20G5krzlKut95m) to read the article now.
Trastuzumab is a monoclonal antibody used in . . .
A new meta-analysis published in the peer-reviewed OMICS: A Journal of Integrative Biology helps shed light on how changes in mitochondria-related gene expression may cause the cardiotoxicity associated with the cancer therapy trastuzumab. Click here (https://email.liebertpub.com/c/11d20G5krzlKut95m) to read the article now.
Trastuzumab is a monoclonal antibody used in . . .